Redhill Biophrma ADR (RDHL) 10.87 $RDHL RedHill (RDHL)

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 7:18 PM

Redhill Biophrma ADR (RDHL) 10.87 $RDHL

RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:11AM CDT
RedHill (RDHL) announced positive results from a phase I study on Yeliva for the treatment of advanced solid tumors.
RDHL: 10.87 (+0.15), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)

RedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection
Globe Newswire - Wed Jun 22, 7:00AM CDT
- The peer-reviewed article, authored by scientists from the University of Central Florida, concludes that the triple combination of the RHB-104 active components provides excellent synergistic activity in the inhibition of mycobacterial growth, potentially leading to a new and effective treatment for Crohn's disease associated with Mycobacterium avium subspecies paratuberculosis (MAP) infection
RDHL: 10.87 (+0.15)

RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA(TM) in Advanced Solid Tumors
Globe Newswire - Tue Jun 21, 8:31AM CDT
- Final results from the Phase I study with YELIVA(TM) (ABC294640) in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina (MUSC), successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity
RDHL: 10.87 (+0.15)

RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA(TM) for IBS-D
GlobeNewswire - Mon Jun 20, 7:00AM CDT
-- The first patients have been dosed in the randomized, double-blind, placebo-controlled Phase II study with BEKINDA 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in 120 subjects in 12 clinical sites in the U.S.
RDHL: 10.87 (+0.15)

RedHill Biopharma to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 15, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Dror Ben-Asher, RedHill's Chief Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference, on Tuesday, June 21, 2016, at 10:30 am EDT, in New York, NY.
RDHL: 10.87 (+0.15)

RedHill Biopharma to Present at the 2016 BIO International Convention
GlobeNewswire - Tue May 31, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Adi Frish, RedHill's Senior VP Business Development & Licensing, will present a corporate overview at the 2016 BIO International Convention, on Tuesday, June 7, 2016, at 11:45 am PDT, at the Moscone Center in San Francisco, CA.
RDHL: 10.87 (+0.15)

RedHill Biopharma to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Mon May 30, 8:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present a corporate overview at the Jefferies 2016 Healthcare Conference, on Wednesday, June 8, 2016, at 10:00 am EDT, in New York, NY.
RDHL: 10.87 (+0.15)

RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA(TM) Phase II Hepatocellular Carcinoma Study
Globe Newswire - Wed May 04, 7:22AM CDT
- The $1.8 million U.S. National Cancer Institute (NCI) grant, awarded to the Medical University of South Carolina (MUSC), is intended to support a research program covering a variety of solid tumor cancers, including a Phase II study with YELIVA(TM) (ABC294640) for the treatment of advanced hepatocellular carcinoma, planned to be initiated in Q3/2016 at MUSC and collaborating institutions
RDHL: 10.87 (+0.15)

RedHill Biopharma to Present at BioNetwork East 2016 Partnering Summit
GlobeNewswire - Mon Apr 25, 7:01AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will present a corporate overview at the BioNetwork East 2016 Partnering Summit, on Monday, May 2, 2016, at 9:20 am EDT, at the Reunion Resort, Orlando, FL.
RDHL: 10.87 (+0.15)

RedHill Biopharma Reports 2016 First Quarter Financial Results
GlobeNewswire - Wed Apr 20, 6:45AM CDT
-- RedHill maintains a strong and debt-free balance sheet with approximately $53 million in cash at the end of the first quarter, allowing the Company to continue to diligently execute its strategic and operational plans, including its three ongoing Phase III gastrointestinal disease programs in the U.S.
RDHL: 10.87 (+0.15)

RedHill Biopharma Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection
Globe Newswire - Mon Apr 18, 7:00AM CDT
- The FDA has confirmed, subject to final minutes of the meeting, the planned two-arm, randomized, double-blind, active comparator design of the confirmatory Phase III study with RHB-105 for the treatment of H. pylori infection, expected to be initiated in the second half of 2016
RDHL: 10.87 (+0.15)

RedHill Biopharma to Host First Quarter 2016 Financial Results Conference Call on April 20, 2016
GlobeNewswire - Wed Apr 13, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it will report its financial results for the first quarter of 2016 on Wednesday, April 20, 2016.
RDHL: 10.87 (+0.15)

RedHill Biopharma Initiates Phase II Study of BEKINDA(TM) for Irritable Bowel Syndrome
Globe Newswire - Mon Apr 11, 8:00AM CDT
- The randomized, double-blind, 2-arm parallel group Phase II study of BEKINDA(TM) 12 mg is expected to enroll 120 patients suffering from diarrhea-predominant irritable bowel syndrome (IBS-D) in 12 clinical sites in the U.S.
RDHL: 10.87 (+0.15)

RedHill Biopharma Announces Interim Results from Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential of RHB-104 in Multiple Sclerosis
Globe Newswire - Thu Mar 31, 7:03AM CDT
- The ongoing CEASE-MS Phase IIa proof-of-concept (PoC), single-arm, open-label study was designed with a series of exploratory endpoints to evaluate the safety and potential efficacy of fixed oral dose RHB-104 as add-on therapy to interferon beta-1a in 18 patients treated for relapsing-remitting multiple sclerosis (RRMS)
RDHL: 10.87 (+0.15)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Egan-Jones Backs DGB's Push for Ethan Allen Shakeup

Proxy Fight Brews Over Ethan Allen's Future Here we are, embroiled in another classic showdown in the corporate boardroom, and this time it's over at Ethan Allen—home of those plush couches and dining tables. Egan-Jones proxy services just threw its weight behind all five of DGB Investment's nominees for Ethan Allen’s board. This kind of tug-of-war isn't new, but each...

Miraculous Medical Team Effort Saves Newborn's Life

A Medical Feat: Teamwork at Its Pinnacle You want a story that restores your faith in humanity? Well, this one from Memorial Healthcare System and Joe DiMaggio Children's Hospital might just do the trick. The tale of baby Jay'ce, born with a neck mass threatening his breath, is straight out of a medical drama—albeit without the Hollywood scriptwriters' spin. It’s rare...

Ares Commercial Real Estate Gears Up for Q3 Earnings

Earnings Season Descends on Ares Commercial Real Estate The hush before the storm is here, comrades. Ares Commercial Real Estate Corporation (NYSE: ACRE) has set the ticker tape rolling as they prepare to unveil the fiscal secrets of their third quarter on November 6, 2026. If you’ve got skin in the game or just an ear for market music, mark your calendars because the...

Tragedy in Jordan: A Call for Unity and Support

A Dark Day in Jordan It's a gut punch, hearing news of yet another brutal attack targeting the Christian community in Jordan's Karak province. This act of terror isn't just a regional dagger—it cuts deep into the fabric of shared humanity. On Friday, the tranquil air of a sacred gathering was shattered, leaving behind grief and a call to action for those who refuse to...

S&P Global's New Dashboard: Unpacking Data Insights

An Interactive Take on Digital Infrastructure The geniuses over at S&P Global Ratings have just unleashed a shiny new tool for number crunchers and market hawks who can't get enough data center action—an interactive dashboard. Maybe not everyone’s cup of tea, but hey, in the dog-eat-dog world of digital infrastructure, any edge counts. What's in the Data Center Soup?...

Cowfest 2026 Delighted by Frederick's Flying Cows

Moo-ving Towards a New Record Alright, listen up. This fall, there's a bovine spectacle coming to Maryland that's more than just a trip down to the fairgrounds—it's Cowfest 2026, baby! Now, if you're scratching your head thinking this is just another seasonal shindig, you're underestimating what's mooing across Frederick County. The Flying Cows are ready to take the...

Qatar's Cultural Ventures Go Big Through 2030

Cultural Partners Lined Up Well Ahead In the swirling world of cultural diplomacy, Qatar's got its eyes set way beyond the skyline with their Years of Culture initiative. Announced recently, they've lined up partners through 2030, locking hands with Italy, the Netherlands, Switzerland, Portugal, and Spain in the coming years. Such moves aren't just for show—they’re...

Ractigen's LiCO™ Platform Hits Extrahepatic Milestones

Breaking New Ground in RNA Therapeutics Hey, in the world of biotech, landing a meaningful delivery system is like striking gold, and it seems Ractigen Therapeutics just found a shiny nugget. Their latest study on the LiCO™ platform, living and breathing in the pages of Molecular Therapy - Nucleic Acids, maps out a path to some serious therapeutic territory. These guys...

University of Phoenix Unveils Credit for Prior Learning Advantages

Navigating College Credits with Life Experience If you think school is the only place to pick up education that counts, think again. University of Phoenix is challenging this by recognizing the value of the hustle and grind working adults go through. During the recently wrapped-up National Transfer Student Week, Devin Andrews, their VP of Admissions and Evaluation, shed...

Italian Excellence: NYC Celebrates Innovators and Icons

The Fusion of Italian Artistry and Innovation Imagine blending business savvy with a touch of culture and ethics. That's the spirit of the 9th Business Care International Award, which is gearing up to hit New York City's grand stage come November 18-19. This ain't just about pats on the back; it's a recognition of those who push Italian excellence across oceans and into...